Default company panoramic image
Presentation2

Laurent Pharmaceuticals

Developing a new treatment paradigm for chronic inflammatory diseases. Lead program in cystic fibrosis (CF), currently in Phase 2.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Montreal, QC, Canada
  • Currency USD
  • Founded November 2012
  • Employees 6
  • Incorporation Type C-corp
  • Website laurentpharma.com

Company Summary

Laurent Pharmaceuticals is a Montréal-based clinical stage company focusing on rare inflammatory diseases. Laurent’s lead candidate, LAU-7b, is a Phase 2 ready oral pro-resolving therapy, a new class of drugs specifically designed to trigger the resolution phase of inflammation. LAU-7b has US-FDA orphan drug designation and is in advanced preparation of a large Phase 2 enroling 136 adult patients with cystic fibrosis in US and Canada.

Team

  • 25c82b84 9b8d 4253 8e02 1ca9d8f731a8
    President and CEO, Director, Co-founder

    Radu Pislariu, MD, is an experienced healthcare entrepreneur, investor and executive, with extensive medical and drug development expertise. Previously with MSBi Valorisation and iNovia Capital, he was involved in creating and/or structuring several biotech companies, which collectively raised more than $150M from private and public sources. The most recent involvements include board positions with Mimetogen and Milestones Pharmaceuticals.

  • Default avatar
    Patrick Colin
    Acting Chief Development Officer, Co-founder

    Dr. Colin is the former VP R&D of Axcan Pharma (now Allergan), and more recently, he co-funded GIcare Pharma, a clinical stage gastroenterology company. His credentials include 27 years of global drug development experience in the US, EU and Canada. Patrick Colin graduated from the Faculty of Pharmacy at the University of Montreal, where he obtained both a professional Pharmacy degree (B.Pharm.) as well as a Ph.D. in Pharmacology.

  • Default avatar
    Danuta Radziock
    Chief Scientific Advisor, Director, Co-founder

    Danuta Radzioch, Ph.D, a Fulbright Scholar, is a Professor of Medicine and Human Genetics at McGill University and a researcher at the Research Institute of the MUHC. Originator of the LAU-7b background technology, Dr. Radzioch is an expert in inflammation associated with chronic respiratory diseases, the mechanism of macrophage activation for bactericidal activity, and genetic factors regulating emphysema and asthma.

  • Default avatar
    France Guay
    Acting Chief Compliance Officer

    Dr. Guay has more than 31 years of experience in quality assurance, compliance and pharmaceutical development. Currently President of FG Pharma, a company specialized in CMC regulatory submissions, Dr. Guay was previously a VP QA and Development with Axan Pharma and Manager with Bristol Myers-Squibb Canada.

  • Default avatar
    Irenej Kianicka
    Acting Senior Director, Drug Development

    Dr. Kianicka is an expert preclinical and clinical drug developer, previously leading early development programs at Vertex, Gemin X, Chronogen and Shire. While at Vertex, he was the co-lead for the development of VX-809 (now Orkambi) and assigned team leader for VX-661 (now in Phase 3).

  • Default avatar
    Jean-Marie Houle
    VP, Clinical Development

    Jean-Marie Houle, Ph.D. Pharm, brings more than 27 years of drug development expertise with particular focus on the management of clinical development operations and logistics. He was previously in VP roles within pharmaceutical and CRO sectors, such as Quintiles, CPR Pharma Services, Anapharm, QLT and Chronogen.

Advisors

  • Default avatar
    BlueHF
    Lawyer
    Unconfirmed
    Default avatar
    Nadine Boucher
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    MSBi Valorisation
    Unconfirmed
    Default avatar
    US Cystic Fibrosis Foundation
    Unconfirmed
    Default avatar
    Cystic Fibrosis Canada
    Unconfirmed
  • Default avatar
    Aligo Innovation
    Unconfirmed
    Default avatar
    RSJ Gradus
    Unconfirmed